Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · New England Journal of Medicine · 21K citations
https://doi.org/10.1056/nejmoa043330
K
Karl Bélanger
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
61
Papers
32.8K
Citations
22
h-index
29
i10-index
Karl Bélanger is an academic researcher from Centre Hospitalier de l’Université de Montréal. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Glioma Diagnosis and Treatment & Brain Metastases and Treatment. The author has an h-index of 22, co-authored 52 publications.
Papers by this author
worksEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
2009 · The Lancet Oncology · 7,668 citations
https://doi.org/10.1016/s1470-2045(09)70025-7
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
2007 · The Lancet Oncology · 543 citations
https://doi.org/10.1016/s1470-2045(07)70384-4
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
2023 · Nature Medicine · 385 citations
https://doi.org/10.1038/s41591-023-02453-x
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
2010 · Journal of Clinical Oncology · 380 citations
https://doi.org/10.1200/jco.2009.26.5520
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
2009 · Cancer Chemotherapy and Pharmacology · 204 citations
https://doi.org/10.1007/s00280-009-1041-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat